source
- Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyoutSanofi has abandoned plans to seek approval for amlitelimab in atopic dermatitis, admitting that a drug once tipped as a potential blockbuster “would not represent a meaningful improvement” to exis…Fierce Biotech · 6d ago↗ source
- Early Alert: Percutaneous Catheter Issue from Boston ScientificENROUTE Transcarotid Neuroprotection Systems may have arterial sheath tip separation or partial tip separation during usefda medwatch · 6d ago↗ source
- Sunny Pharmtech, Inc. Issues Voluntary Nationwide Recall of Cyclophosphamide for Injection, USP to the User Level Due to the Presence of Particulate MatterJuly 24, 2026 - Taoyuan City, Taiwan - Sunny Pharmtech, Inc is voluntarily recalling three lots of Cyclophosphamide for Injection, USP, 1g/vial and 2g/vial, to the User Level due to the presence of…